Therapeutic Application of Empagliflozin, Sitagliptin, and Metformin for Advancing Overall Wellness in T2D: Evidence Review for Practitioners in 2025 Dr. Manoj Chadha19 Feb 2026 10:35 AM ISTHyperglycemia in T2D plays a pivotal role in diabetic microvascular complications; however, reducing HbA1c offers only modest benefit in mitigating...
Lifestyle-Linked CV Risk: Where Does Aspirin Fit? Dr. Nishant Tripathy13 Feb 2026 12:45 PM ISTIndia faces a rapidly evolving cardiometabolic risk landscape, with overweight and obesity affecting 23.5% and 6.7% of adults, alongside escalating...
Redefining Diabetes Management With Dapagliflozin and Sitagliptin FDC: An Early, Effective and Sustainable Option For T2D Management With Risk Factors Dr. Vaishali Deskhmukh12 Feb 2026 12:40 PM ISTType 2 diabetes in Indians follows a distinct and more aggressive trajectory, marked by higher insulin resistance, early Beta-cell dysfunction, lower...
Obesity-Prediabetes Duo: Why Clinicians Must Intervene Early? Dr. Siddhant Milind Dahale4 Feb 2026 12:30 PM ISTPrediabetes is alarmingly common, with the IDF 2025 Atlas estimating nearly 90 million Indians are affected. [1] Escalating obesity,...
Robust Glycemic Control & Cardio-Renal Protection: Meeting the Advanced Needs of Indian Uncontrolled T2D with Empagliflozin, Sitagliptin, Metformin Dr. Nilanjan Sengupta28 Jan 2026 12:45 PM ISTIndia has an estimated 90 million people living with T2D [1] amid rising obesity and doubled management costs. Uncontrolled T2DM and early-onset...
Dapagliflozin and Sitagliptin FDC in T2D with Heart Failure: 2025 Indian Practice Review Dr. Santosh H.S.17 Jan 2026 11:39 AM ISTAmong India's 89.8 million people with T2D [1], heart failure incidence reaches approximately 50%, with 33% higher hospitalization risk versus...
Latest Triple Combination of Empagliflozin, Sitagliptin, and Metformin for Advanced Care in Indian T2DM Patients- When to Consider? Dr. (Col) Sudhir Tripathi9 Jan 2026 11:37 AM ISTDiabetes mellitus affects nearly 90 million Indians (IDF 2025) [1], with the Indian phenotype conferring disproportionately higher cardiorenal risk...
Early-Onset Hypertension and Elevated ASCVD Risk: When Does Aspirin Fit? Dr. Laxman Gaikwad1 Jan 2026 11:30 AM ISTThe epidemiology of hypertension in India has undergone a malignant shift, moving from a disease of the elderly to a pervasive condition in the...
Cardio-Metabolic Risk and Aspirin: What Does the Evidence Say for Indian Patients? Dr. Deepak Gupta19 Dec 2025 11:30 AM ISTIndia carries a heavy cardiometabolic burden of nearly 30%, intensified by early-onset diabetes, hypertension, dyslipidaemia, and obesity patterns...
Uncontrolled T2DM in India and Application of Trusted Molecules Empagliflozin, Sitagliptin, and Metformin Coming Together Dr. Sunil M Jain10 Dec 2025 11:13 AM ISTThe Growing Burden of Uncontrolled T2DM in India: The burden of diabetes in India has risen markedly, yet only around 7% of individuals with diagnosed...
Managing GERD in Children with Asthma with H2 receptor antagonists (H2RAs): Indian Paediatricians' Perspectives Dr. Garima Soni5 Dec 2025 12:30 PM ISTGastroesophageal reflux disease (GERD) symptoms extend beyond typical esophageal symptoms such as heartburn and regurgitation, with asthma emerging...
Undenatured Collagen in Long-Term OA Joint Health: Beyond Symptom Control Dr. Sunny Kumar Mallick1 Dec 2025 10:47 AM ISTOsteoarthritis (OA), the most prevalent musculoskeletal disease in India, affects over 62 million people, with a prevalence of 22-30%.[1,2] The burden...
